Browsing Tag
Sanofi
62 posts
Can Sanofi’s molecular clamp bet with Vicebio challenge mRNA leaders in respiratory vaccines?
Can Sanofi’s $1.15B Vicebio deal challenge Pfizer and Moderna’s mRNA RSV dominance? Explore how molecular clamp vaccines could change respiratory protection.
July 25, 2025
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
July 22, 2025
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
June 11, 2025
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.
June 4, 2025
Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy
Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.
May 23, 2025
Viz.ai partners with Sanofi and Regeneron to use AI for advancing COPD care across U.S. hospitals
Viz.ai teams up with Sanofi and Regeneron to launch AI-powered COPD care module for faster diagnosis, better outcomes, and real-time care coordination.
May 20, 2025
Novavax shares rally after FDA approves non-mRNA COVID-19 vaccine for at-risk groups
Novavax stock surged 25% after FDA approved its non-mRNA COVID-19 vaccine Nuvaxovid. Find out what triggered this rally and what it means for investors.
May 19, 2025
Sanofi advances flu vaccine production with FDA-approved strains for 2025-26 season
Sanofi has confirmed that it is advancing its flu vaccine production for the 2025-26 flu season, aligning with…
March 15, 2025
Scribe Therapeutics unveils ELXR technology breakthrough at Keystone Symposia 2025
Scribe Therapeutics has presented new data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia…
March 7, 2025
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…
February 28, 2025